Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Opposes Enzi/Kennedy Drug Safety Bill; Action More Likely Through PDUFA

Executive Summary

Pending drug safety legislation from Sens. Michael Enzi (R-Wyo.) and Edward Kennedy (D-Mass.) may do more harm than good, FDA implied in comments submitted to the Senate Health Committee

You may also be interested in...



Hassan Urges Incoming Congress To Sustain U.S. Biomedical Strength

Schering-Plough CEO Fred Hassan is urging newly elected members of Congress to help preserve the strength of the U.S. biomedical industry in the face of rising foreign competition

Hassan Urges Incoming Congress To Sustain U.S. Biomedical Strength

Schering-Plough CEO Fred Hassan is urging newly elected members of Congress to help preserve the strength of the U.S. biomedical industry in the face of rising foreign competition

Democratic Capitol Hill Will Create Challenges For Brand Industry

The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act

Related Content

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel